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Abstract 
Colorectal cancer is one of the most common malignancies in the world. Many mouse models have 
been developed to evaluate features of colorectal cancer in humans. These can be grouped into 
genetically鄄  engineered, chemically鄄  induced, and inoculated models. However, none recapitulates all of the 
characteristics of human colorectal cancer. It is critical to use a specific mouse model to address a 
particular research question. Here, we review commonly used mouse models for human colorectal cancer. 
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Colorectal cancer is the third most common 
malignancy in the world. In the United States, colorectal 
cancer is the fourth most commonly diagnosed cancer 
and the second leading cause of cancer­related death [1] . 
The development of colorectal cancer is a process 
sequentially acquiring a number of genetic changes in 
normal epithelium, which enables precancerous cells to 
develop into an adenomatous polyp and progress into an 
invasive tumor (Figure 1)  [2] . Inactivation of the 
adenomatous polyposis coli (  ) gene and activation 
of the  proto­oncogene are two early events of 
colorectal tumorigenesis  [3,4] . Germline mutation of the 
gene causes the familial adenomatous polyposis 
(FAP) syndrome. However, lesions exhibiting 
mutation without  alteration result mostly in 
non­dysplastic lesions with limited potential to progress 
to carcinoma [5] . The next step in progression from 
adenoma to carcinoma is the loss of heterozygosity of 
chromosome 18q, which contains candidate tumor 
suppressor genes including  ,  and  [6] . 
Mutation of  on chromosome 17q appears to be a 
late­stage event [2] . Some genetic changes do not affect 
the cell biology of the tumor but instead result in loss of 
genomic stability. As evidenced in patients with 
hereditary non­polyposis colorectal cancer (HNPCC), 
loss of DNA mismatch repair (MMR) genes leads to 
microsatellite instability (MSI) and early­onset colorectal 
tumors [7,8] . In addition to MSI, colorectal cancer can 
develop chromosomal instability (CIN), which also occurs 
relatively early in tumor evolution [8­12] . 
The laboratory mouse is one of the best model 
systems in biomedical research because of the 
availability of genetic/genomic information on individual 
murine lines and techniques to construct transgenic and 
knockout mice. Many mouse models for colorectal 
cancer have been generated and can be grouped as 
genetically­engineered, chemically­induced, and 
inoculated models. As none of these models recapitulate 
the process of colorectal cancer development in its 
entirety, it is important to use a specific model to 
address a particular scientific question. Here, we review 
commonly used mouse models for human colorectal 
cancer (Table 1). 
Mouse Models for Familial Adenoma鄄  
tous Polyposis (FAP) 
FAP is a hereditary disease with high penetrance 
that causes numerous polyps throughout the colon and 
rectum. Human  gene is commonly deleted in many 
kindreds with FAP [13,14] .  functions as a tumor 
suppressor to down­regulate the canonical WNT 
signaling pathway by binding to and promoting the 
degradation of 茁  ­catenin protein [15] . Loss of  impairs 
茁  ­catenin degradation [15,16] . The accumulated 茁  ­catenin 
moves to the nucleus, where it activates TCF/LEF 
transcription factors that transactivate Wnt­targeted 
genes [17] . Activation of the canonical WNT pathway is a 
key event in colorectal tumorigenesis [18] . 
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Human disease 
FAP 
HNPCC 
Inflammation鄄  related 
colorectal cancer 
Sporadic colorectal 
cancer 
Metastatic colorectal 
cancer 
Mouse model 
Apc mutants or 茁  鄄  catenin transgenic 
mice 
Msh2 -/- , Msh6 -/- , and Mlh1 -/- mice 
DSS鄄  induced mouse models 
IL10 -/- , IL2 -/- , T鄄  cell receptor -/- /p53 -/- 
or TGF鄄  1 -/- /Rag鄄  2 -/- 
Muc2 -/- 
Carcinogen鄄  induced mouse model 
Cre adenovirus鄄  mediated Apc 
inactivation 
Orthotopic inoculation model 
Intrasplenic inoculation model 
Intraportal inoculation model 
Intrahepatic inoculation model 
Advantages and disadvantages 
Mimic APC mutation in human. However, most tumors located in the small 
intestine. Tumors are not metastatic. 
Mimic MMR deficiency in human. However, MMR鄄  deficient mice develop tumors 
in other organs. The colonic tumors are not metastatic. 
Easy and reproducible. Tumor incidence is low. AOM/DSS combination produces 
more tumors at earlier time point. 
Tumor incidence is low. Requires the involvement of enteric microflora. 
High incidence of colon and rectal tumors. Early development of rectal prolapse 
reduces life span. 
Easy and reproducible. DMH/AOM/MAM have relatively high colorectal tumor 
incidence. IQ, PhIP, DMAB, MNNG or MNU target multiple organs and exhibit a 
low tumor incidence. The tumors are not metastatic. 
Require surgical procedures. Results are reproducible. Develop metastasis in 
~20% of animals. 
Mimics colon tumor invasion, vascular spread, and metastasis to distal organ. 
Metastasis rates depend on cell lines and rodent strains. 
Reproducible and mimics vascular spread of colorectal cancer. Metastasis rates 
depend on cell lines and rodent strains. 
Mimics vascular spread of colorectal cancer metastasis and theoretically limits 
tumor growth predominantly to the liver. Metastasis rates depend on cell lines 
and rodent strains. 
Model is reproducible but does not mimic the generally accepted hypothesis of 
hematogenous spread of colorectal cancer. 
FAP, familial adenomatous polyposis; HNPCC, hereditary nonpolyposis colorectal cancer; MMR, mismatch repair; DSS, dextran sulfate sodium; MAM, 
methylazoxymethanol; DMH, 1,2鄄  dimethylhydrazine; AOM, azoxymethane; PhIP, 2鄄  amino鄄  1鄄  methyl鄄  6鄄  phenylimidazo[4,5鄄  b]pyridine; IQ, 2鄄  amino鄄  33鄄  methylimidazo 
[4,5鄄  f] quinoline; DMAB, 3,2忆鄄  dimethyl鄄  4鄄  aminobiphenyl; MNU, methylnitrosourea; MNNG, N鄄  methyl鄄  N忆鄄  nitro鄄  N鄄  nitrosoguanidine. 
Figure 1. 
Inactivation of the adenomatous polyposis coli (APC) gene and 
activation of 茁  鄄  catenin are early events of colorectal tumorigenesis. Activation of the K鄄  Ras and B鄄  Raf proto鄄  oncogenes promotes tumorigenesis. The next step 
in progression from adenoma to carcinoma is the loss functions of candidate tumor suppressor genes including SMAD4/TGFBR2 and CDC4. Mutation of p53/ 
BAX and IGF2R appears to be a late鄄  stage event. Some genetic changes do not affect the cell biology of the tumor but instead result in loss of genomic 
stability. For example, colorectal cancer can develop chromosomal instability (CIN), which also occurs relatively early in tumor evolution. Loss of DNA mismatch 
repair (MMR) genes leads to microsatellite instability (MSI) and early鄄  onset colorectal tumors. ACF, aberrant crypt foci. 
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The first murine  gene mutation, named  Min 
(multiple intestinal neoplasia), was identified in a colony 
of mice following random mutagenesis [19] . This mutation 
is a truncating mutation at codon 850 of the  gene [20] . 
Homozygote  Min  mice are embryonic lethal, whereas 
heterozygote  Min  mice on a C57BL/6 background 
typically develop ~30 polyps, the majority of which occur 
in the small intestine [19,21] . Using homologous recombination 
in embryonic stem cells, several additional  mutants 
have been constructed:  Δ 716 , which contains a 
truncating mutation at codon 716  [22] ;  1638N , which 
contains a neomycin insertion in exon 15 that produces a 
truncating mutation at codon 1638;  1638T , which 
contains a hygromycin insertion in exon 15 resulting in a 
truncating mutation at codon 1638  [23] ;  Δ 14 , which 
contains a frameshift at codon 580 [24] ;  1309 , which 
contains a frameshift at codon 1309 [25] ;  Δ 580 , which 
contains a frameshift at codon 580 and a truncation at 
codon 605 [26] ; and  Δ 474 , which contains a frameshit at 
codon 474 [27] . The polyp adenomas of these  ­mutant 
mice are histologically indistinguishable from each other, 
but the number of polyps developed is very different, 
even in the same C57BL/6J background. The  Δ 716 
mouse develops ~300 polyps, Apc 1638N  mouse develops 
~3,  Δ 14 mouse develops ~65,  1309 mouse develops 
~35,  Δ 580  mouse develops ~120, and  Δ 474  mouse 
develops ~30 [16] . Similar to Apc Min  mice, these mutant 
mice primarily develop polyps in the small intestine. 
Comparing to Apc Min  mice, despite the significant 
increase in polyps in the small intestine, there is no 
increase in polyps in the colon in mice with some Apc 
mutants, such as  Δ 716 . In addition to early onset of 
gastrointestinal tumors,  Min  mice show progressive 
loss of immature and mature thymocytes from ~80 days 
of age, with complete regression of the thymus by 120 
days [28] . Also, splenic natural killer cells, immature B 
cells, and B progenitor cells are depleted in the bone 
marrow.  Min  mice have perturbations in ammonia 
metabolism in the liver [29] . Circulating interferon­6 (IL­6) 
increases 10­fold, causing severe cachexia as 
exemplified by loss of muscle weight and fat tissues [30] . 
Due to these complications, most  ­mutant mice die 
young (4 to 5 months). 
Additional mouse models have been developed to 
test genes affecting tumorigenesis in mice with 
mutations.  mutations are very common in 
colorectal cancers. Constitutively active mutant 
(  ) promotes colorectal tumor development in 
­heterozygous mice. Adenocarcinomas expressing 
invariably exhibit uniform high­grade dysplasia 
throughout the gut, but this does not occur in mice 
expressing wild­type  [31] . Mice that are homozygous 
for the  conditional knockout (CKO) allele and 
heterozygous for a latent activated allele of 
(  tm4tyj/+ ) develop advanced tumors and eventually 
form liver metastasis [32] . COX­2 is expressed in early 
stage of polyp formation [33] . Knockout of  gene 
(  ) in  Δ 716 mice dramatically reduces the number 
and size of polyps in these compound mutant mice [33,34] . 
Mutation in the  gene in  Δ 716  mice results in 
most polyps occurring in the colon [35] .  ­mutant mice 
exhibit an increased frequency of loss of heterozygosity 
(LOH) of the  gene due to chromosomal instability, 
which may result from activation of the mTOR pathway 
and acceleration of the G 1  to S phase transition in the 
cell cycle. Introduction of a  R1+/­  mutation into  Min 
mice causes a 10­fold increase in the number of colonic 
tumors compared to  Min  mice  [36] . Both  ­ and 
­mutant mice exhibit a higher rate of genomic 
instability [35,36] , making them good models for prevention 
and treatment of colon cancers with chromosomal 
instability. Introduction of  mutation into  Δ 716 
polyposis mice results in locally invasive malignant 
adenocarcinomas without metastasis [37] . The histopatho­ 
logic manifestations are similar to human right­sided 
colon cancer, which is associated with mutations in the 
type II receptor of transforming growth factor (TGF)­茁  . 
Consistently, homozygous disruption of the type II 
receptor of the  gene (  ) in  1638N  mice 
causes malignant transformation of the intestinal 
adenomas induced by  mutation [38] . Inactivation of 
cyclin­dependent kinase inhibitors (CDKI)  and 
significantly enhances intestinal tumorigenesis in the 
1638N  mice  [39,40] . These  1638N  compound mouse 
models highlight the importance of  , but not  , in 
colon cancer prevention by non­steroidal anti­ 
inflammatory drugs (NSAID)  [39,40] .  Min  mice with 
heterozygous disruption of  develop invasive 
carcinomas that are large, making this a good animal 
model for studying persistent activation of the 
phosphatidylinositol 3­kinase/Akt pathway in colorectal 
cancer [41] . Recently, mutation of  in  Min mice has 
been reported to promote progression of colon adenoma 
to cancer [42] , suggesting that this model could be useful 
to study tumor progression. 
Hereditary Non鄄  polyposis Colorectal 
Cancer (HNPCC) Models 
HNPCC (Lynch syndrome) is one of the most 
prevalent malignancies in the western world and 
accounts for about 5% of all colorectal cancers. Patients 
with HNPCC develop early­onset tumors in the colon and 
rectum, and a subset of patients also develop tumors in 
the stomach, small intestine, ovaries, and endometrium [43] . 
Patients with HNPCC carry a mutant allele of the DNA 
MMR genes, such as  ,  , and  [44­46] . 
Upon mutation of the wild­type allele by somatic events, 
the cells become MMR­deficient, and their genomic DNA 
Mouse models of colorectal cancer 
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displays increased rates of replication errors at short 
repeat sequences, which is termed microsatellite 
instability (MSI) [47­49] . 
Heterozygous  ,  , and  knockout mice 
do not develop early­onset tumors, but homozygous 
,  , and  knockout mice are cancer­prone, 
developing tumors in multiple organs including the 
gastrointestinal tract. These homozygous knockout mice 
die prematurely due to aggressive lymphomas, which are 
very similar to patients with biallelic mismatch repair 
mutations [50,51] . These phenotypes in humans and mice 
suggest that the basic mechanisms of DNA repair and 
tumor suppression are conserved. 
murine cells are unable to repair single­base 
mismatches and 1­ to 4­base insertion/deletion loops 
(IDLs). The loss of MMR in these mice causes a severe 
reduction in survival and a strong cancer predisposition 
phenotype [52,53] . Most  mice die from T­cell lymphomas 
by 6 to 8 months, and those that survive often develop 
small intestinal adenomas and invasive 
adenocarcinomas. Similar to tumors in patients with 
HNPCC, the tumors in  mice have high MSI [53] . To 
avoid early death caused by tumorigenesis in other 
organs, conditional  knockout mice, in which 
intestine­specific gene inactivation is permitted, have 
been generated using either  or  . 
These mice develop tumors that highly mimic tumors 
developed by patients with Lynch syndrome, which make 
the mice useful preclinical models [54] . 
­deficient mice survive longer (up to 18 
months) and develop tumors at an older age than 
­deficient mice  [55] .  ­deficient cells exhibit 
dysfunctional repair of base substitution mutations and 
single­base IDLs. Because  ­/­  mice predominantly 
have base substitution mutations rather than frame shift 
mutations, tumors in these mice do not display the MSI 
phenotype that is a characteristic of HNPCC. In parallel, 
individuals with germ­line  mutations frequently 
have atypical HNPCC characterized by cancer onset at 
more than 60 years old and a variable MSI phenotype [56] . 
Moreover,  ­/­  mice also develop endometrial 
cancers, which is consistent with a significant number of 
patients with  mutations [57] . 
­/­  mice exhibit complete MMR deficiency, have 
a shortened life span (up to 12 months) and a strong 
cancer predisposition, similar to  ­deficient mice. 
The tumor spectrum of  ­/­  mice includes T­cell 
lymphomas, intestinal adenomas and adenocarcinomas, 
and skin tumors, which are high MSI [58­60] . 
A significant number of MSI­positive human 
colorectal cancers carry somatic mutations in the 
gene, indicating that loss of APC function is critical for 
tumor initiation and/or progression in MMR­deficient 
tumors. Mice that have homozygous mutations of  , 
,  , or  and heterozygous germ­line 
mutations of  develop tumors almost exclusively in 
the intestinal tract [61­64] . Specifically, in  mutant mice, 
functional loss of  or  dramatically increases 
intestinal tumors [61,62] , while functional loss of  or 
moderately increases intestinal tumors [ 63 , 64 ] . 
Functional loss of  , on the other hand, does not 
increase the tumor load  [64] . The incidence of tumors 
correlates with the severity of the MMR defects in MMR 
knockout mice. 
Chemically Induced Colorectal Cancer 
Models 
Carcinogen induced colorectal cancer in mice is 
rapid and reproducible, and recapitulates the adenoma­to­ 
adenocarcinoma sequence that occurs in humans. The 
availability of genetically鄄  engineered or specific inbred 
mice add further value to these models. Commonly used 
carcinogens include the following: 1) 
methylazoxymethanol (MAM), 1,2­dimethylhydrazine 
(DMH), and azoxymethane (AOM); 2) heterocyclic 
amines (HCAs), such as 2­amino­1­methyl­6­ 
phenylimidazo [4,5­b]pyridine (PhIP) and 2­amino­33­ 
methylimidazo [4,5­f] quinoline (IQ); 3) aromatic amines, 
such as 3,2忆  ­dimethyl­4­aminobiphenyl (DMAB); and 4) 
alkylnitrosamide compounds, such as methylnitrosourea 
(MNU) and N­methyl­N忆  ­nitro­N­nitrosoguanidine (MNNG). 
MAM was first identified in Cycad flour and found to 
be carcinogenic in both humans and rats [65,66] . DMH and 
AOM (DMH metabolite) are MAM precursors, which 
require metabolic activation to form DNA­reactive 
products  [67­69] . The reactive metabolite, MAM, readily 
yields a methyl diazonium ion that can alkylate 
macromolecules in the liver and colon [67,70,71] , including 
guanine (by adding methyl groups at either the O6 or N7 
position to form O6­methyl­deoxyguanosine or 
N7­methyl­deoxyguanosine). Repetitive treatment with 
DMH produces colon tumors in rodents that exhibit many 
of the pathologic features associated with the human 
disease [72­74] ; thus, it represents a reliable, reproducible 
experimental system for studying sporadic (non­familial) 
colorectal cancer. AOM is advantageous over DMH 
because of its stronger potency and greater stability 
during administration [75] . As in human populations, inbred 
murine strains differ in their sensitivity to colon 
carcinogens. SWR/J and A/J mice are sensitive to AOM 
and develop up to 20 tumors in the distal colon, whereas 
AKR/J mice are resistant and rarely develop tumors [76,77] . 
Also, FVB/N and Balb/c murine strains that are 
commonly used for constructing gene knockout and 
transgenic animals, develop approximately four tumors 
and one tumor per mouse, respectively, upon treatment 
with AOM  [76,77] . The 129SvJ, C57Bl/6J, AKR/J, and 
DBA/2J mice are relatively resistant to AOM and DMH [77] . 
In contrast, DMH induces colon cancer with moderate 
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success in Balb/cHeA and SWR/J mice and with high 
success in A/J, P/J, STS/A, and ICR/Ha mice [78­82] . 
Interestingly, the morphology of AOM­induced dysplasia 
appears nearly identical between these mouse strains 
even though they exhibit a difference in their sensitivity 
to colon cancer development  [ 83 ] . The reason for this 
strain­specific difference in carcinogen sensitivity is not 
clear, but data suggest involvement of subsequent 
carcinogenic steps such as tumor promotion rather than 
the result of differences in carcinogen metabolism [84] . 
HCAs, including IQ and PhIP, are mutagens usually 
formed upon broiling fish and meat [85­87] . The precursors 
of IQ­type HCAs are creatinine, amino acids, and sugars 
in fish and meat [87] . IQ requires metabolic activation by 
liver microsomes for conversion to its ultimate 
carcinogen, and subsequently form high levels of DNA 
adducts in a number of organs [88­90] . PhIP (4 weekly 
intraperitoneal injection at 50 mg/kg body weight) 
increases the number of small tumors and cystic crypts 
in the small/large intestines in  Min  mice, but only 
induces a few aberrant crypt foci (ACF) in the large 
intestines in wild­type mice  [91] . Both IQ and PhIP induce 
intestinal tumors in  Min  mice associated with 
inactivation of the wild­type  allele, either by causing 
LOH or truncation mutations [92] . Rats who receive either 
IQ or PhIP have a high frequency of colon, mammary 
gland, and prostate cancers [93­96] . However, the incidence 
of colon tumor is low, ranging from 5% to 28% when 
these agents are administered in the diet for up to 52 
weeks [97] . Short­term intermittent feeding of 400 mg/kg 
PhIP in combination with a high­fat diet results in 
accelerated tumor formation [93] . Thus, the HCA­induced 
colon cancer model is useful to investigate the 
chemopreventive activity of potential agents against 
colon carcinogenesis. 
DMAB, an aromatic amine, was first reported to be 
a colonic carcinogen in rats in 1952  [98] . Interestingly, 
injections of DMAB to male F344 rats (weekly 
subcutaneous injection at 50 mg/kg body weight) 
induced multiple colon tumors in 27% and 75% of rats 
fed either a low­fat or high­fat diet, respectively  [99,100] . 
DMAB induced both adenomas and adenocarcinomas, 
with a multiplicity of 1.2  to 2.7 tumors per tumor­bearing 
rat. DMAB is less potent in rodent models than DMH or 
AOM. It is less organ­specific and induces neoplasms in 
mammary and salivary glands, ear ducts, skin, 
forestomach, and urinary bladder [73,101,102] . 
MNNG and MNU are direct alkylating agents that do 
not require metabolic activation. Intrarectal instillation of 
MNU or MNNG in rodents induces colorectal tumors [103­105] 
that are predominantly sessile or polypoid lesions. For 
example, intrarectal administration of MNNG (1  to 3 
mg/week) for 20 weeks induced colon tumors at the 
injection site in all male F344 rats (57% adenomas, 
43% adenocarcinomas )  [104,105] . Most of the resultant 
adenocarcinomas were well differentiated with infiltration 
into the submucosa, but a minority was poorly 
differentiated and showed mucinous cancer cells 
infiltrating into the submucosa. As no biochemical 
activation is required for MNU or MNNG action, these 
carcinogens are ideal for studying the modifying effects 
of xenobiotics in colorectal tumorigenesis without 
involving carcinogen metabolism [106] . 
Taken together, all of these carcinogens cause 
mutations and deletions in a spectrum of genes that are 
known to be involved in human colon cancer 
tumorigenesis.  activating mutations (G to A) were 
found in 66% of DMH­induced colon carcinomas [107]  and 
33% of MNU­generated carcinomas [108] .  mutations 
are frequent in MNU­induced rat colon tumors. In 
contrast,  but not  and  mutations are 
frequently observed in AOM­induced lesions [109­111] . 
mutations are frequent [112,113] but  mutations are rare 
in PhIP­induced colon tumors [114] . In carcinogen­induced 
rodent colon tumors not having  mutations, 
mutations can occur [115­117] , indicating the importance of 
the Wnt/Apc/茁  ­catenin signaling pathway in chemically­ 
induced rodent colon carcinogenesis. 
Inflammation鄄  Related Colorectal Cancer 
Models 
Inflammation plays important roles in the 
development of colorectal cancer; the risk increases with 
the extent and duration of inflammation. Colorectal 
cancer is one of the most serious complications 
associated with long­standing inflammatory bowel 
disease (IBD). Several mouse models for 
inflammation­related colorectal cancer have been 
developed, including dextran sodium sulphate (DSS) 
­induced colitis models and genetically engineered 
models. 
DSS鄄  induced colitis model 
The most commonly used colitis mouse model uses 
DSS  [118] . Colorectal cancer development following 
DSS­induced inflammation suggests that chronic 
inflammation in IBD plays a critical role in epithelial 
malignant neoplasia of the colon and rectum [119] . This 
model is DSS dose­dependent and typically requires a 
relatively long exposure period and low repeated cycles 
of DSS administration  [120] . The incidence and/or 
multiplicity of DSS­induced colorectal tumors are 
relatively low [121] . To promote tumorigenesis, mice are 
often treated with AOM and DSS and then develop 
tumors after a relatively short­term exposure [122] . Different 
strains of mice exhibit distinct susceptibilities to 
AOM/DSS­induced colon carcinogenesis [120] . For 
example, nearly 100% Balb/c mice developed colonic 
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adenocarcinoma, with a multiplicity of 7.7 依  4.3; in 
contrast, only 50% of C57BL/6N mice formed tumors, 
with a multiplicity of 1.0 依 1.2; and even less robustly, 
both C3H/HeN and DBA/2N mice developed only a few 
colonic adenomas  [120] . In addition, DSS­treated  Min 
mice also develop more colon tumor than vehicle 
control­treated ones [123] . 
In the AOM/DSS model, dysplastic lesions are 
initially formed in the colonic mucosa. Both dysplasia 
and neoplasia stain positive for  ­  ,  , and 
inducible nitric oxide synthase but not  . Mutations of 
the  ­  gene occur in 80% to 100% of AOM­induced 
or DMH/DSS­induced colonic adenocarcinomas [123,124] . Mice 
developing colonic adenocarcinomas often have 
mutations of the  ­  gene at codons 32 to 34 if the 
mice receive AOM/DSS [123]  or at codons 33, 37, and 41 if 
the mice receive AOM  [117] . Collectively, these results 
suggest that mutations at codons 33 and 34 might be 
caused by AOM exposure, whereas mutations at 
codon 32 may result from DSS exposure [117,125] . Gene 
expression of Wnt inhibitory factor 1 (  ), plasminogen 
activator (  ), myelocytomatosis oncogene (  ), and 
phospholipase A2 group IIA (platelets and synovial fluid) 
(  ) are up­regulated, and the inflammation­related 
gene, peroxisome proliferator­activated receptor­酌  
(  ), PPAR­binding protein (  ), and  are 
down­regulated at 5 to 10 weeks of AOM/DSS 
exposure  [126] . Similar to the AOM/DSS model, mice 
receiving the colon carcinogens (PhIP and DMH) 
followed by DSS treatment have a higher incidence of 
tumors [124,127] . 
Genetically engineered IBD mouse models 
The immune system plays an important role in the 
etiology of colonic inflammation. Disruption of the 
immune response to antigenic stimuli is strongly 
associated with IBD and IBD­related colorectal cancer. 
IL­2­ and IL­10­defective mice develop IBD similar to 
humans. The level of inflammation in IL­10­defective 
mice correlates with the incidence of colorectal 
adenocarcinomas [128] . The combination of IL­2 deficiency 
with 2­microglobulin deficiency in mice causes colonic 
inflammation, and some of these mice develop 
adenocarcinoma of the proximal colon  [129,130] . Notably, 
IL­2­ and IL­10­defective mice, as well as either T­cell 
receptor/p53­  or TGF­1/Rag­2­deficient mice, do not 
develop chronic inflammation or intestinal tumors when 
maintained under germ­free conditions, suggesting that 
the enteric microflora plays an important role in the 
development of IBD and IBD­associated cancers in 
these mice [131­134] . 
Activation of nuclear factor­资  B (NF­资  B) and 
correlated pro­inflammatory cytokines and adhesion 
molecules are required for inflammation­related intestinal 
neoplasia [135,136] . Studies with  (  ) knockout 
mice indicate  is a positive regulator of NF­资  B and 
IL­1茁   secretion and increases susceptibility to 
inflammation induced by bacteria in the intestine [137,138] . 
Blocking NF­ 资  B signaling reduces colonic inflammation 
and carcinogenesis in the AOM/DSS model [135,137­140] . 
Chronic colitis appears to require activation of the 
Toll­like receptor­4 (TLR4). Genetically, Tlr4­deficient 
mice have decreased levels of Cox­2 and Pge2 
expression, as well as activation of the epidermal growth 
factor receptor signaling pathway. These mice are also 
more resistant than wild­type mice to the development of 
colitis [139] . Inhibition of TLR4 or tumor necrosis factor­琢  
signaling could be useful in treating IBD­associated 
dysplastic colonic tissue. 
Another genetically engineered colorectal mouse 
model is the  ­/­  mouse.  encodes the major 
gastrointestinal mucin, which forms an insoluble mucous 
barrier that protects the intestinal lumen [141­143] . Targeted 
inactivation of  causes tumor formation throughout 
the intestinal tract, including the colon and rectum  [141] . 
­/­  mice have a chronic intestinal inflammation 
associated with up­regulation of  and cytokines, 
increased cell migration and proliferation, and decreased 
apoptosis. However, unlike other mouse colon cancer 
models, such as  Min and  1638+/­ mice [19,144] , the  ­catenin 
pathway is not involved in tumorigenesis  [141,145,146] . 
Inactivation of  in  ­/­  mice significantly increases 
tumorigenesis, possibly through down­regulating  and 
up­regulating  [40] .  ­/­  mice possessing an 
mutation have significantly increased colorectal 
carcinogenesis, perhaps through an interaction between 
­  and chronic inflammation [146] . 
Metastatic Colorectal Cancer Models 
Almost a third of patients with colorectal cancer 
have metastatic disease at the time of diagnosis. 
Moreover, half of the patients who are diagnosed with 
and undergo resection for early­stage disease 
subsequently develop metastasis. Metastatic colorectal 
cancer is difficult to treat and, ultimately, nearly all 
patients die of their disease  [147] . Mice that are 
genetically­engineered or carcinogen­induced to develop 
colon cancer rarely develop metastasis. In contrast, 
models using transplant colorectal cancers can exhibit 
high rates of metastasis and recapitulate some of the 
desired characteristics. 
Orthotopic implantation is defined as the inoculation 
of tumor cells/tissue in the intestine, for example, cecum 
or rectum [148] . This method mimics colon tumor invasion, 
vascular spread, and metastasis to distal organs. The 
metastasis rates depend on cell type, implantation site, 
and rodent strain. For example, colon cancer MCA­38 
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and RCN­9 cells produced liver metastasis in 40% to 65% 
of mice 8 weeks after intramural injection into the cecal 
wall of C57BL/6J mice [149,150] . Liver metastases have also 
occurred by inoculating human colon cancer tissues 
orthotopically in nude mice [151,152] . The histological features 
of the transplanted tumors may help determine the 
success of liver metastasis formation  [152] . However, 
neither mouse colon carcinoma CT­26 cells (in Balb/c), 
MCA­38 cells (in C57BL/6J), nor DHD/K12­PROb cells 
(in BD­IX rats) developed liver metastasis when injected 
into the wall of the rectum or cecum [153,154] . Orthotopic 
implantation of colon cancer cells into mice has also 
resulted in metastasis to lymph nodes and other sites. 
Three human colon cancer cell lines (HCT­116, SW­620, 
and DLD­1) orthotopically injected into the cecal wall of 
nude mice showed varying degrees of mesenteric and 
retroperitoneal lymphatic invasion, hematogenous 
dissemination to the liver and lungs, as well as peritoneal 
carcinomatosis (29% to 100% ) [155] . Another series of 
experiments placing human colon cancer in the cecal 
wall of immunodeficient mice showed that lymph node 
metastases occurred most frequently using HCC2998 
and HT29 cells. SW620 cells gave rise to multiple 
small (2  to 3 mm) metastatic hepatic nodules, and 
CaCo2, WiDr, and Co205 cells had very low rates of 
metastasis [156] . 
Intrasplenic injection of tumor cells mimics the 
vascular spread of colorectal cancer. This procedure is 
relatively easy and consistently induces liver metastases. 
Mortality caused by either splenic injection or local tumor 
growth can be controlled by splenectomy following 
injection [157] . Paradoxically, in one series of experiments, 
liver metastasis occurred more frequently when 
moderate to well differentiated cells (CX­1, HT­29, 
CCL188, and CCL235) but not poorly differentiated cells 
(MIP­101, Clone A, CCL222, and CCL231) were 
intrasplenically injected  [158] . In another series of 
intrasplenic injection­induced liver metastasis 
experiments, many of the human colon cancer cells 
( metastatic capability : COLO320DM and HCT116 
>HT­29, WiDr and LoVo > LS174T) spread to the liver, 
with a frequency ranging from 50% to 100% of mice. 
CaCo2, COLO201, LS123, SW48, and SW1417 cells 
showed no metastasis after 1 伊 10 4 cells were injected [159] . 
Rodent colorectal cancer cells also exhibit different 
metastatic capabilities. Mouse colon cancer MCA­38 
cells and mucinous colon adenocarcinoma WB­2054­M4 
cells efficiently developed liver metastases in C57BL/6J 
mice and Wistar/Furth 伊 Brown­Norwegian hybrid rats, 
respectively, when injected intrasplenically [160,161] . However, 
K12­TR cells failed to develop liver metastases after 
injection into the spleens of BD­1X rats, as well as nude 
rats and mice [162] . 
Intraportal injection of tumor cells mimics the 
vascular spread of colorectal cancer metastasis and 
theoretically limits tumor growth to the liver. Current data 
show that this procedure reproducibly results in liver 
metastases in almost all animals. Partial hepatic 
ischemia before injection of tumor cells further increases 
the number of hepatic metastases, likely due to 
up­regulation of expression of adhesion molecules 
induced during hepatic ischemia [163,164] . WB­2054­M cells, 
originally from a lung metastasis, yielded liver 
metastases in 50% of Wistar/Furth ×  Brown­Norwegian 
hybrid rats  [165] . Colon cancer CC531, LDLX40, 
DHDK12/TR, and LMCR cells developed liver metastasis 
in all Wistar, WAG/Rij, and BDIX rats when injected into 
the portal vein [166­172] . 
Intrahepatic (subcapsular or intraparenchymal) 
implantation of tumor cells is a widely used method to 
create liver metastases. The model is reproducible and 
has acceptable complication rates. However, as this 
method does not mimic the generally accepted 
hypothesis of hematogenous spread of colorectal cancer, 
these tumors might not reflect the human situation, and, 
therefore, may behave aberrantly to therapeutic 
interventions. Despite this disadvantage, such induction 
of tumors has been used by many investigators to study 
local therapy of metastases. For example, CC531 as 
well as N­methyl­N­nitrosoguanidine (NNG) induced 
colon adenocarcinoma cells develop tumors in all 
animals in several weeks when injected into the liver of 
WAG/Rij or Wistar rats respectively  [173­178] , and 
DHDK12/TR cells develop tumors in BD­IX rats in all 
animals 6 weeks after injection  [179] . Intrahepatic 
implantation of tumor fragments of human colon cancer, 
derived from a liver metastasis of a patient, resulted in 
100% liver metastases after only 10 days [180] . 
Conclusions and Future Direction 
A variety of mouse models of human colorectal 
cancer have been developed, and each imitates, in part, 
human colon carcinogenesis. These models allow rapid 
and repeated interrogation of hypotheses, and each 
produces a method to test various therapeutic modalities 
that would not be possible in humans. 
Genetically­engineered mice models are useful for 
studying the importance of specific genomic alterations 
in the development and progression of colorectal cancer 
and their sensitivity to various therapies. The 
chemically­induced mouse models mimic human 
sporadic colorectal cancer and are often used to study 
dietary influences on carcinogenesis. The inoculated 
colorectal cancer models recapitulate some features of 
colorectal cancer metastasis and are useful models for 
anti­metastatic drug evaluation. Even though each 
mouse model recapitulates an aspect of human 
colorectal cancer, the power of these models to predict 
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clinical efficacy of treatments may be limited. Genetic 
and chemical mouse models may not reproduce the 
complexity of the human disease, and injection of human 
and murine colon cancer cell lines might be hampered 
because the long­term cultured cell line might have 
accumulated features that no longer reflect the 
characteristics of freshly isolated tumor cells. Also, 
differences in mouse size and physiology, as well as 
variations in colon cancer that develops in mice and 
humans may also lead to translational limitations. 
Nevertheless, each system has the exciting and robust 
capacity to model human colon cancer, facilitating a 
better and more rapid understanding of its etiology and 
providing new opportunities for developing and rapidly 
testing novel therapies. 
Acknowledgements 
This study was sponsored by the NIH/NCI grant 
K99CA138914 (YT), CA112081 (WY), R01CA02603831 
and an A*STAR Investigator Grant (HPK). 
Received: 2011­02­09; accepted: 2011­02­18. 
References 
Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 [J]. CA 
Cancer J Clin, 2010,60(5):277-300. 
Fearon ER, Vogelstein B. A genetic model for colorectal 
tumorigenesis [J]. Cell, 1990,61(5):759-767. 
Nagase H, Nakamura Y. Mutations of the apc (adenomatous 
polyposis coli) gene [J]. Hum Mutat, 1993,2(6):425-434. 
Forrester K, Almoguera C, Han K, et al. Detection of high 
incidence of k鄄  ras oncogenes during human colon 
tumorigenesis [J]. Nature, 1987,327(6120):298-303. 
Jen J, Powell SM, Papadopoulos N, et al. Molecular 
determinants of dysplasia in colorectal lesions [J]. Cancer Res, 
1994,54(21):5523-5526. 
Kern SE, Fearon ER, Tersmette KW, et al. Clinical and 
pathological associations with allelic loss in colorectal 
carcinoma [corrected] [J]. JAMA, 1989,261(21):3099-3103. 
Jiricny J, Nystrom鄄  Lahti M. Mismatch repair defects in cancer 
[J]. Curr Opin Genet Dev, 2000,10(2):157-161. 
Aaltonen LA, Peltomaki P, Mecklin JP, et al. Replication errors 
in benign and malignant tumors from hereditary nonpolyposis 
colorectal cancer patients [J]. Cancer Res, 1994,54 (7):1645- 
1648. 
Jacoby RF, Marshall DJ, Kailas S, et al. Genetic instability 
associated with adenoma to carcinoma progression in 
hereditary nonpolyposis colon cancer [J]. Gastroenterology, 
1995,109(1):73-82. 
Bomme L, Bardi G, Pandis N, et al. Cytogenetic analysis of 
colorectal adenomas: Karyotypic comparisons of synchronous 
tumors [J]. Cancer Genet Cytogenet, 1998,106(1):66-71. 
Ried T, Heselmeyer鄄  Haddad K, Blegen H, et al. Genomic 
changes defining the genesis, progression, and malignancy 
potential in solid human tumors: a phenotype/genotype 
correlation [J]. Genes Chromosomes Cancer, 1999,25(3):195- 
204. 
Rooney PH, Murray GI, Stevenson DA, et al. Comparative 
genomic hybridization and chromosomal instability in solid 
tumours [J]. Br J Cancer, 1999,80(5-6):862-873. 
Groden J, Thliveris A, Samowitz W, et al. Identification and 
characterization of the familial adenomatous polyposis coli gene 
[J]. Cell, 1991,66(3):589-600. 
Kinzler KW, Nilbert MC, Vogelstein B, et al. Identification of a 
gene located at chromosome 5q21 that is mutated in colorectal 
cancers [J]. Science, 1991,251(4999):1366-1370. 
Polakis P. The oncogenic activation of beta鄄  catenin [J]. Curr 
Opin Genet Dev, 1999,9(1):15-21. 
McCart AE, Vickaryous NK, Silver A. Apc mice: models, 
modifiers and mutants [J]. Pathol Res Pract, 2008,204(7):479- 
490. 
Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional 
activation by a beta鄄  catenin鄄  tcf complex in apc -/- colon 
carcinoma [J]. Science, 1997,275(5307):1784-1787. 
Oshima H, Oshima M, Kobayashi M, et al. Morphological and 
molecular processes of polyp formation in apc (delta716) 
knockout mice [J]. Cancer Res, 1997,57(9):1644-1649. 
Moser AR, Pitot HC, Dove WF. A dominant mutation that 
predisposes to multiple intestinal neoplasia in the mouse [J]. 
Science, 1990,247(4940):322-324. 
Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal 
neoplasia caused by a mutation in the murine homolog of the 
apc gene [J]. Science, 1992,256(5057):668-670. 
Halberg RB, Katzung DS, Hoff PD, et al. Tumorigenesis in the 
multiple intestinal neoplasia mouse: redundancy of negative 
regulators and specificity of modifiers [J]. Proc Natl Acad Sci 
U S A, 2000,97(7):3461-3466. 
Oshima M, Oshima H, Kitagawa K, et al. Loss of apc 
heterozygosity and abnormal tissue building in nascent 
intestinal polyps in mice carrying a truncated apc gene [J]. 
Proc Natl Acad Sci U S A, 1995,92(10):4482-4486. 
Pretlow TP, Edelmann W, Kucherlapati R, et al. Spontaneous 
aberrant crypt foci in apc1638n mice with a mutant apc allele 
[J]. Am J Pathol, 2003,163(5):1757-1763. 
Colnot S, Niwa鄄  Kawakita M, Hamard G, et al. Colorectal 
cancers in a new mouse model of familial adenomatous 
polyposis: influence of genetic and environmental modifiers [J]. 
Lab Invest, 2004,84(12):1619-1630. 
Quesada CF, Kimata H, Mori M, et al. Piroxicam and acarbose 
as chemopreventive agents for spontaneous intestinal 
adenomas in apc gene 1309 knockout mice [J]. Jpn J Cancer 
Res, 1998,89(4):392-396. 
Kuraguchi M, Wang XP, Bronson RT, et al. Adenomatous 
polyposis coli (apc) is required for normal development of skin 
and thymus [J]. PLoS Genet, 2006,2(9):e146. 
Sasai H, Masaki M, Wakitani K. Suppression of polypogenesis 
in a new mouse strain with a truncated apc (delta474) by a 
novel cox鄄  2 inhibitor, jte鄄  522 [J]. Carcinogenesis, 2000,21(5): 
953-958. 
Coletta PL, Muller AM, Jones EA, et al. Lymphodepletion in the 
apcmin/+ mouse model of intestinal tumorigenesis [J]. Blood, 
2004,103(3):1050-1058. 
Mouse models of colorectal cancer 
457
Chinese Journal of Cancer Chin J Cancer; 2011; Vol. 30 Issue 7 
Benhamouche S, Decaens T, Godard C, et al. Apc tumor 
suppressor gene is the 野zonation鄄  keeper冶 of mouse liver [J]. 
Dev Cell, 2006,10(6):759-770. 
Baltgalvis KA, Berger FG, Pena MM, et al. Interleukin鄄  6 and 
cachexia in apcmin/+ mice [J]. Am J Physiol Regul Integr 
Comp Physiol, 2008,294(2):R393-401. 
Haigis KM, Kendall KR, Wang Y, et al. Differential effects of 
oncogenic k鄄  ras and n鄄  ras on proliferation, differentiation and 
tumor progression in the colon [J]. Nat Genet, 2008,40 (5): 
600-608. 
Hung KE, Maricevich MA, Richard LG, et al. Development of a 
mouse model for sporadic and metastatic colon tumors and its 
use in assessing drug treatment [J]. Proc Natl Acad Sci U S A, 
2010,107(4):1565-1570. 
Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of 
intestinal polyposis in apc delta716 knockout mice by inhibition 
of cyclooxygenase 2 (cox鄄  2) [J]. Cell, 1996,87(5):803-809. 
Oshima M, Murai N, Kargman S, et al. Chemoprevention of 
intestinal polyposis in the apcdelta716 mouse by rofecoxib, a 
specific cyclooxygenase鄄  2 inhibitor [J]. Cancer Res, 2001,61 
(4):1733-1740. 
Aoki K, Tamai Y, Horiike S, et al. Colonic polyposis caused by 
mtor鄄  mediated chromosomal instability in apc+/delta716 cdx2+/- 
compound mutant mice [J]. Nat Genet, 2003,35(4):323-330. 
Rao CV, Yang YM, Swamy MV, et al. Colonic tumorigenesis in 
bubr1+/-apcmin/+ compound mutant mice is linked to 
premature separation of sister chromatids and enhanced 
genomic instability [J]. Proc Natl Acad Sci U S A, 2005,102 
(12):4365-4370. 
Takaku K, Oshima M, Miyoshi H, et al. Intestinal tumorigenesis 
in compound mutant mice of both dpc4 (smad4) and apc 
genes [J]. Cell, 1998,92(5):645-656. 
Munoz NM, Upton M, Rojas A, et al. Transforming growth 
factor beta receptor type ii inactivation induces the malignant 
transformation of intestinal neoplasms initiated by apc mutation 
[J]. Cancer Res, 2006,66(20):9837-9844. 
Yang WC, Mathew J, Velcich A, et al. Targeted inactivation of 
the p21 (waf1/cip1) gene enhances apc鄄  initiated tumor 
formation and the tumor鄄  promoting activity of a western鄄  style 
high鄄  risk diet by altering cell maturation in the intestinal 
mucosal [J]. Cancer Res, 2001,61(2):565-569. 
Yang W, Velcich A, Lozonschi I, et al. Inactivation of p21waf1/ 
cip1 enhances intestinal tumor formation in muc2-/- mice [J]. 
Am J Pathol, 2005,166(4):1239-1246. 
Shao J, Washington MK, Saxena R, et al. Heterozygous 
disruption of the pten promotes intestinal neoplasia in apcmin/+ 
mouse: roles of osteopontin [J]. Carcinogenesis, 2007,28(12): 
2476-2483. 
Petrova TV, Nykanen A, Norrmen C, et al. Transcription factor 
prox1 induces colon cancer progression by promoting the 
transition from benign to highly dysplastic phenotype [J]. 
Cancer Cell, 2008,13(5):407-419. 
Lynch HT, Smyrk T. Hereditary nonpolyposis colorectal cancer 
(lynch syndrome). An updated review [J]. Cancer, 1996,78(6): 
1149-1167. 
Peltomaki P. Role of DNA mismatch repair defects in the 
pathogenesis of human cancer [J]. J Clin Oncol, 2003,21 (6): 
1174-1179. 
Vasen HF, Boland CR. Progress in genetic testing, 
classification, and identification of lynch syndrome [J]. JAMA, 
2005,293(16):2028-2030. 
Rustgi AK. The genetics of hereditary colon cancer [J]. Genes 
Dev, 2007,21(20):2525-2538. 
Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the 
pathogenesis of familial colorectal cancer [J]. Science, 
1993,260(5109):812-816. 
Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic 
mutations in simple repeated sequences reveal a new 
mechanism for colonic carcinogenesis [J]. Nature, 1993,363 
(6429):558-561. 
Umar A. Lynch syndrome (hnpcc) and microsatellite instability 
[J]. Dis Markers, 2004,20(4-5):179-180. 
Edelmann L, Edelmann W. Loss of DNA mismatch repair 
function and cancer predisposition in the mouse: animal 
models for human hereditary nonpolyposis colorectal cancer 
[J]. Am J Med Genet C Semin Med Genet, 2004,129C(1):91- 
99. 
Felton KE, Gilchrist DM, Andrew SE. Constitutive deficiency in 
DNA mismatch repair [J]. Clin Genet, 2007,71(6):483-498. 
de Wind N, Dekker M, Berns A, et al. Inactivation of the 
mouse msh2 gene results in mismatch repair deficiency, 
methylation tolerance, hyperrecombination, and predisposition 
to cancer [J]. Cell, 1995,82(2):321-330. 
Reitmair AH, Redston M, Cai JC, et al. Spontaneous intestinal 
carcinomas and skin neoplasms in msh2鄄  deficient mice [J]. 
Cancer Res, 1996,56(16):3842-3849. 
Taketo MM, Edelmann W. Mouse models of colon cancer [J]. 
Gastroenterology, 2009,136(3):780-798. 
Edelmann W, Yang K, Umar A, et al. Mutation in the mismatch 
repair gene msh6 causes cancer susceptibility [J]. Cell, 
1997,91(4):467-477. 
Kolodner RD, Tytell JD, Schmeits JL, et al. Germ鄄  line msh6 
mutations in colorectal cancer families [J]. Cancer Res, 
1999,59(20):5068-5074. 
Wijnen J, de Leeuw W, Vasen H, et al. Familial endometrial 
cancer in female carriers of msh6 germline mutations [J]. Nat 
Genet, 1999,23(2):142-144. 
Baker SM, Plug AW, Prolla TA, et al. Involvement of mouse 
mlh1 in DNA mismatch repair and meiotic crossing over [J]. 
Nat Genet, 1996,13(3):336-342. 
Edelmann W, Cohen PE, Kane M, et al. Meiotic pachytene 
arrest in mlh1鄄  deficient mice [J]. Cell, 1996,85(7):1125-1134. 
Prolla TA, Baker SM, Harris AC, et al. Tumour susceptibility 
and spontaneous mutation in mice deficient in mlh1, pms1 and 
pms2 DNA mismatch repair [J]. Nat Genet, 1998,18 (3):276- 
279. 
Edelmann W, Yang K, Kuraguchi M, et al. Tumorigenesis in 
mlh1 and mlh1/apc1638n mutant mice [J]. Cancer Res, 
1999,59(6):1301-1307. 
Reitmair AH, Cai JC, Bjerknes M, et al. Msh2 deficiency 
contributes to accelerated apc鄄  mediated intestinal 
tumorigenesis [J]. Cancer Res, 1996,56(13):2922-2926. 
Baker SM, Harris AC, Tsao JL, et al. Enhanced intestinal 
adenomatous polyp formation in pms2-/-;min mice [J]. Cancer 
Res, 1998,58(6):1087-1089. 
Kuraguchi M, Yang K, Wong E, et al. The distinct spectra of 
tumor鄄  associated apc mutations in mismatch repair鄄  deficient 
apc1638n mice define the roles of msh3 and msh6 in DNA 
repair and intestinal tumorigenesis [J]. Cancer Res, 2001,61 
(21):7934-7942. 
Laqueur GL, Mickelsen O, Whiting MG, et al. Carcinogenic 
properties of nuts from cycas circinalis l. Indigenous to guam 
[J]. J Natl Cancer Inst, 1963,31:919-951. 
Laqueur GL. Carcinogenic effects of cycad meal and cycasin, 
methylazoxymethanol glycoside, in rats and effects of cycasin 
in germfree rats [J]. Fed Proc, 1964,23:1386-1388. 
咱29暂 
咱30暂 
咱31暂 
咱32暂 
咱33暂 
咱34暂 
咱35暂 
咱36暂 
咱37暂 
咱38暂 
咱39暂 
咱40暂 
咱41暂 
咱42暂 
咱43暂 
咱44暂 
咱45暂 
咱46暂 
咱47暂 
咱48暂 
咱49暂 
咱50暂 
咱51暂 
咱52暂 
咱53暂 
咱54暂 
咱55暂 
咱56暂 
咱57暂 
咱58暂 
咱59暂 
咱60暂 
咱61暂 
咱62暂 
咱63暂 
咱64暂 
咱65暂 
咱66暂 
Yunguang Tong et al. Mouse models of colorectal cancer 
458
Chin J Cancer; 2011; Vol. 30 Issue 7 www.cjcsysu.com 
Fiala ES. Investigations into the metabolism and mode of action 
of the colon carcinogens 1,2鄄  dimethylhydrazine and 
azoxymethane [J]. Cancer, 1977,40(5 Suppl):2436-2445. 
Fiala ES, Joseph C, Sohn OS, et al. Mechanism of 
benzylselenocyanate inhibition of azoxymethane鄄  induced colon 
carcinogenesis in f344 rats [J]. Cancer Res, 1991,51 (11): 
2826-2830. 
Weisburger JH. Colon carcinogens: their metabolism and mode 
of action [J]. Cancer, 1971,28(1):60-70. 
Fiala ES, Caswell N, Sohn OS, et al. Non鄄  alcohol 
dehydrogenase鄄  mediated metabolism of methylazoxymethanol 
in the deer mouse, peromyscus maniculatus [J]. Cancer Res, 
1984,44(7):2885-2891. 
Fiala ES, Kulakis C, Christiansen G, et al. Inhibition of the 
metabolism of the colon carcinogen, azoxymethane, by 
pyrazole [J]. Cancer Res, 1978,38(12):4515-4521. 
Haase P, Cowen DM, Knowles JC. Histogenesis of colonic 
tumours in mice induced by dimethyl hydrazine [J]. J Pathol, 
1973,109(1):Px. 
Martin MS, Martin F, Michiels R, et al. An experimental model 
for cancer of the colon and rectum. Intestinal carcinoma 
induced in the rat 1,2鄄  dimethylhydrazine [J]. Digestion, 1973,8 
(1):22-34. 
Ward JM. Morphogenesis of chemically induced neoplasms of 
the colon and small intestine in rats [J]. Lab Invest, 1974,30 
(4):505-513. 
Neufert C, Becker C, Neurath MF. An inducible mouse model 
of colon carcinogenesis for the analysis of sporadic and 
inflammation鄄  driven tumor progression [J]. Nat Protoc, 2007,2 
(8):1998-2004. 
Delker DA, Wang QS, Papanikolaou A, et al. Quantitative 
assessment of azoxymethane鄄  induced aberrant crypt foci in 
inbred mice [J]. Exp Mol Pathol, 1999,65(3):141-149. 
Nambiar PR, Girnun G, Lillo NA, et al. Preliminary analysis of 
azoxymethane induced colon tumors in inbred mice commonly 
used as transgenic/knockout progenitors [J]. Int J Oncol, 
2003,22(1):145-150. 
Boffa LC, Diwan BA, Gruss R, et al. Differences in colonic 
nuclear proteins of two mouse strains with different 
susceptibilities to 1, 2鄄  dimethylhydrazine鄄  induced 
carcinogenesis [J]. Cancer Res, 1980,40(6):1774-1780. 
Deschner EE, Long FC, Hakissian M. Susceptibility to 1,2鄄  
dimethylhydrazine鄄  induced colonic tumors and epithelial cell 
proliferation characteristics of f1, f2, and reciprocal 
backcrosses derived from swr/j and akr/j parental mouse 
strains [J]. Cancer, 1988,61(3):478-482. 
Diwan BA, Dempster AM, Blackman KE. Effects of 
methylazoxymethanol acetate on inbred mice: influence of 
genetic factors on tumor induction [J]. Proc Soc Exp Biol Med, 
1979,161(3):347-349. 
Evans JT, Shows TB, Sproul EE, et al. Genetics of colon 
carcinogenesis in mice treated with 1,2鄄  dimethylhydrazine [J]. 
Cancer Res, 1977,37(1):134-136. 
Rosenberg DW, Liu Y. Induction of aberrant crypts in murine 
colon with varying sensitivity to colon carcinogenesis [J]. 
Cancer Lett, 1995,92(2):209-214. 
Papanikolaou A, Wang QS, Papanikolaou D, et al. Sequential 
and morphological analyses of aberrant crypt foci formation in 
mice of differing susceptibility to azoxymethane鄄  induced colon 
carcinogenesis [J]. Carcinogenesis, 2000,21(8):1567-1572. 
Papanikolaou A, Shank RC, Delker DA, et al. Initial levels of 
azoxymethane鄄  induced DNA methyl adducts are not predictive 
of tumor susceptibility in inbred mice [J]. Toxicol Appl 
Pharmacol, 1998,150(1):196-203. 
Nagao M, Honda M, Seino Y, et al. Mutagenicities of smoke 
condensates and the charred surface of fish and meat [J]. 
Cancer Lett, 1977,2(4-5):221-226. 
Sugimura T, Wakabayashi K, Nakagama H, et al. Heterocyclic 
amines: mutagens/carcinogens produced during cooking of 
meat and fish [J]. Cancer Sci, 2004,95(4):290-299. 
Jagerstad M, Reutersward AL, Grivas S, et al. Effects of meat 
composition and cooking conditions on the formation of 
mutagenic imidazoquinoxalines (meiqx and its methyl 
derivatives) [J]. Princess Takamatsu Symp, 1985,16(87-96. 
Kato R. Metabolic activation of mutagenic heterocyclic aromatic 
amines from protein pyrolysates [J]. Crit Rev Toxicol, 1986,16 
(4):307-348. 
Schut HA, Putman KL, Randerath K. DNA adduct formation of 
the carcinogen 2鄄  amino鄄  3鄄  methylimidazo [4,5鄄  f]鄄  quinoline in 
target tissues of the f鄄  344 rat [J]. Cancer Lett, 1988,41 (3): 
345-352. 
Tanaka T, Barnes WS, Williams GM, et al. Multipotential 
carcinogenicity of the fried food mutagen 2鄄  amino鄄  3鄄  
methylimidazo [4,5鄄  f]quinoline in rats [J]. Jpn J Cancer Res, 
1985,76(7):570-576. 
Andreassen A, Vikse R, Mikalsen A, et al. 2鄄  amino鄄  1鄄  methyl鄄  6鄄  
phenylimidazo [4,5鄄  b]pyridine (phip) induces genetic changes 
in murine intestinal tumours and cells with apcmin mutation [J]. 
Mutat Res, 2006,604(1-2):60-70. 
Andreassen A, Mollersen L, Vikse R, et al. One dose of 2鄄  
amino鄄  1鄄  methyl鄄  6鄄  phenylimidazo [4,5鄄  b]pyridine (phip) or 2鄄  
amino鄄  3鄄  methylimidazo [4,5鄄  f]quinoline (iq) induces tumours in 
min/+ mice by truncation mutations or loh in the apc gene [J]. 
Mutat Res, 2002,517(1-2):157-166. 
Nakagama H, Nakanishi M, Ochiai M. Modeling human colon 
cancer in rodents using a food鄄  borne carcinogen, phip [J]. 
Cancer Sci, 2005,96(10):627-636. 
Shirai T, Sano M, Tamano S, et al. The prostate: a target for 
carcinogenicity of 2鄄  amino鄄  1鄄  methyl鄄  6鄄  phenylimidazo [4,5鄄  b] 
pyridine (phip) derived from cooked foods [J]. Cancer Res, 
1997,57(2):195-198. 
Ito N, Hasegawa R, Imaida K, et al. Carcinogenicity of 2鄄  
amino鄄  1鄄  methyl鄄  6鄄  phenylimidazo [4,5鄄  b]pyridine (phip) in the 
rat [J]. Mutat Res, 1997,376(1-2):107-114. 
Chen C, Ma X, Malfatti MA, et al. A comprehensive 
investigation of 2鄄  amino鄄  1鄄  methyl鄄  6鄄  phenylimidazo [4,5鄄  b] 
pyridine (phip) metabolism in the mouse using a multivariate 
data analysis approach [J]. Chem Res Toxicol, 2007,20 (3): 
531-542. 
Reddy BS, Rivenson A. Inhibitory effect of bifidobacterium 
longum on colon, mammary, and liver carcinogenesis induced 
by 2鄄  amino鄄  3鄄  methylimidazo [4,5鄄  f]quinoline, a food mutagen 
[J]. Cancer Res, 1993,53(17):3914-3918. 
Walpole AL, Williams MH, Roberts DC. The carcinogenic action 
of 4鄄  aminodiphenyl and 3:2爷鄄  dimethyl鄄  4鄄  amino鄄  diphenyl [J]. Br 
J Ind Med, 1952,9(4):255-263. 
Reddy BS, Ohmori T. Effect of intestinal microflora and dietary fat 
on 3,2爷鄄  dimethyl鄄  4鄄  aminobiphenyl鄄  induced colon carcinogenesis 
in f344 rats [J]. Cancer Res, 1981,41(4):1363-1367. 
Spjut HJ, Noall MW. Experimental induction of tumors of the 
large bowel of rats. A review of the experience with 3鄄  2' 
dimethyl鄄  4鄄  aminobiphenyl [J]. Cancer, 1971,28(1):29-37. 
Decaens C, Gautier R, Daher N, et al. Induction of rat 
intestinal carcinogenesis with single doses, low and high 
repeated doses of 1,2鄄  dimethylhydrazine [J]. Carcinogenesis, 
1989,10(1):69-72. 
咱67暂 
咱68暂 
咱69暂 
咱70暂 
咱71暂 
咱72暂 
咱73暂 
咱74暂 
咱75暂 
咱76暂 
咱77暂 
咱78暂 
咱79暂 
咱80暂 
咱81暂 
咱82暂 
咱83暂 
咱84暂 
咱85暂 
咱86暂 
咱87暂 
咱88暂 
咱89暂 
咱90暂 
咱91暂 
咱92暂 
咱93暂 
咱94暂 
咱95暂 
咱96暂 
咱97暂 
咱98暂 
咱99暂 
咱100暂 
咱101暂 
Yunguang Tong et al. Mouse models of colorectal cancer 
459
Chinese Journal of Cancer Chin J Cancer; 2011; Vol. 30 Issue 7 
Ward JM. Dose response to a single injection of azoxymethane 
in rats. Induction of tumors in the gastrointestinal tract, auditory 
sebaceous glands, kidney, liver and preputial gland [J]. Vet 
Pathol, 1975,12(3):165-177. 
Narisawa T, Magadia NE, Weisburger JH, et al. Promoting 
effect of bile acids on colon carcinogenesis after intrarectal 
instillation of n鄄  methyl鄄  n'鄄  nitro鄄  n鄄  nitrosoguanidine in rats [J]. J 
Natl Cancer Inst, 1974,53(4):1093-1097. 
Narisawa T, Weisburger JH. Colon cancer induction in mice by 
intrarectal instillation of n鄄  methylnitosorurea (38498) [J]. Proc 
Soc Exp Biol Med, 1975,148(1):166-169. 
Narisawa T, Sato T, Hayakawa M, et al. Carcinoma of the 
colon and rectum of rats by rectal infusion of n鄄  methyl鄄  n'鄄  nitro鄄  
n鄄  nitrosoguanidine [J]. Gann, 1971,62(3):231-234. 
Reddy BS, Narisawa T, Maronpot R, et al. Animal models for 
the study of dietary factors and cancer of the large bowel [J]. 
Cancer Res, 1975,35(11 Pt. 2):3421-3426. 
Jacoby RF, Llor X, Teng BB, et al. Mutations in the k鄄  ras 
oncogene induced by 1,2鄄  dimethylhydrazine in preneoplastic 
and neoplastic rat colonic mucosa [J]. J Clin Invest, 1991,87 
(2):624-630. 
Jacoby RF, Alexander RJ, Raicht RF, et al. K鄄  ras oncogene 
mutations in rat colon tumors induced by n鄄  methyl鄄  n鄄  
nitrosourea [J]. Carcinogenesis, 1992,13(1):45-49. 
Bolt AB, Papanikolaou A, Delker DA, et al. Azoxymethane 
induces ki鄄  ras activation in the tumor resistant akr/j mouse 
colon [J]. Mol Carcinog, 2000,27(3):210-218. 
De Filippo C, Caderni G, Bazzicalupo M, et al. Mutations of 
the apc gene in experimental colorectal carcinogenesis 
induced by azoxymethane in f344 rats [J]. Br J Cancer, 
1998,77(12):2148-2151. 
Erdman SH, Wu HD, Hixson LJ, et al. Assessment of mutations 
in ki鄄  ras and p53 in colon cancers from azoxymethane鄄 and 
dimethylhydrazine鄄  treated rats [J]. Mol Carcinog, 1997,19 (2): 
137-144. 
Kakiuchi H, Watanabe M, Ushijima T, et al. Specific 5'鄄  ggga鄄  3' 
邛 5'鄄  gga鄄  3' mutation of the apc gene in rat colon tumors 
induced by 2鄄  amino鄄  1鄄  methyl鄄  6鄄  phenylimidazo [4,5鄄  b]pyridine 
[J]. Proc Natl Acad Sci U S A, 1995,92(3):910-914. 
Matsumoto K, Iwase T, Hirono I, et al. Demonstration of ras 
and p53 gene mutations in carcinomas in the forestomach and 
intestine and soft tissue sarcomas induced by n鄄  methyl鄄  n鄄  
nitrosourea in the rat [J]. Jpn J Cancer Res, 1997,88(2):129- 
136. 
Kakiuchi H, Ushijima T, Ochiai M, et al. Rare frequency of 
activation of the ki鄄  ras gene in rat colon tumors induced by 
heterocyclic amines: possible alternative mechanisms of human 
colon carcinogenesis [J]. Mol Carcinog, 1993,8(1):44-48. 
Dashwood RH, Suzui M, Nakagama H, et al. High frequency of 
beta鄄  catenin (ctnnb1) mutations in the colon tumors induced 
by two heterocyclic amines in the f344 rat [J]. Cancer Res, 
1998,58(6):1127-1129. 
Blum CA, Tanaka T, Zhong X, et al. Mutational analysis of 
ctnnb1 and apc in tumors from rats given 1,2鄄  
dimethylhydrazine or 2鄄  amino鄄  3鄄  methylimidazo [4,5鄄  f]quinoline: 
mutational 野hotspots冶 and the relative expression of beta鄄  
catenin and c鄄  jun [J]. Mol Carcinog, 2003,36(4):195-203. 
Takahashi M, Nakatsugi S, Sugimura T, et al. Frequent 
mutations of the beta鄄  catenin gene in mouse colon tumors 
induced by azoxymethane [J]. Carcinogenesis, 2000,21 (6): 
1117-1120. 
Okayasu I, Hatakeyama S, Yamada M, et al. A novel method 
in the induction of reliable experimental acute and chronic 
ulcerative colitis in mice [J]. Gastroenterology, 1990,98(3):694- 
702. 
Seril DN, Liao J, Yang GY, et al. Oxidative stress and 
ulcerative colitis鄄  associated carcinogenesis: studies in humans 
and animal models [J]. Carcinogenesis, 2003,24(3):353-362. 
Suzuki R, Kohno H, Sugie S, et al. Strain differences in the 
susceptibility to azoxymethane and dextran sodium sulfate鄄  
induced colon carcinogenesis in mice [J]. Carcinogenesis, 
2006,27(1):162-169. 
Okayasu I, Yamada M, Mikami T, et al. Dysplasia and 
carcinoma development in a repeated dextran sulfate sodium鄄  
induced colitis model [J]. J Gastroenterol Hepatol, 2002,17 
(10):1078-1083. 
Tanaka T, Kohno H, Suzuki R, et al. A novel inflammation鄄  
related mouse colon carcinogenesis model induced by 
azoxymethane and dextran sodium sulfate [J]. Cancer Sci, 
2003,94(11):965-973. 
Tanaka T, Suzuki R, Kohno H, et al. Colonic adenocarcinomas 
rapidly induced by the combined treatment with 2鄄  amino鄄  1鄄  
methyl鄄  6鄄  phenylimidazo [4,5鄄  b]pyridine and dextran sodium 
sulfate in male icr mice possess beta鄄  catenin gene mutations 
and increases immunoreactivity for beta鄄  catenin, 
cyclooxygenase鄄  2 and inducible nitric oxide synthase [J]. 
Carcinogenesis, 2005,26(1):229-238. 
Kohno H, Suzuki R, Sugie S, et al. Beta鄄  catenin mutations in a 
mouse model of inflammation鄄  related colon carcinogenesis 
induced by 1,2鄄  dimethylhydrazine and dextran sodium sulfate 
[J]. Cancer Sci, 2005,96(2):69-76. 
Koesters R, Hans MA, Benner A, et al. Predominant mutation 
of codon 41 of the beta鄄  catenin proto鄄  oncogene in rat colon 
tumors induced by 1,2鄄  dimethylhydrazine using a complete 
carcinogenic protocol [J]. Carcinogenesis, 2001,22 (11):1885 - 
1890. 
Suzuki R, Miyamoto S, Yasui Y, et al. Global gene expression 
analysis of the mouse colonic mucosa treated with 
azoxymethane and dextran sodium sulfate [J]. BMC Cancer, 
2007,7:84. 
Cheung C, Loy S, Li GX, et al. Rapid induction of colon 
carcinogenesis in CYP1A鄄  humanized mice by 2鄄  amino鄄  1鄄  
methyl鄄  6鄄  phenylimidazo [4,5鄄  b]pyridine and dextran sodium 
sulfate [J]. Carcinogenesis, 2011,32(2):233-239. 
Berg DJ, Davidson N, Kuhn R, et al. Enterocolitis and colon 
cancer in interleukin鄄  10鄄  deficient mice are associated with 
aberrant cytokine production and cd4 (+ ) th1鄄  like responses 
[J]. J Clin Invest, 1996,98(4):1010-1020. 
Simpson SJ, Mizoguchi E, Allen D, et al. Evidence that cd4+ , 
but not cd8 + t cells are responsible for murine interleukin鄄  2鄄  
deficient colitis [J]. Eur J Immunol, 1995,25(9):2618-2625. 
Shah SA, Simpson SJ, Brown LF, et al. Development of colonic 
adenocarcinomas in a mouse model of ulcerative colitis [J]. 
Inflamm Bowel Dis, 1998,4(3):196-202. 
Schultz M, Tonkonogy SL, Sellon RK, et al. Il鄄  2鄄  deficient mice 
raised under germfree conditions develop delayed mild focal 
intestinal inflammation [J]. Am J Physiol, 1999,276 (6 Pt 1): 
G1461-1472. 
Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric 
bacteria are necessary for development of spontaneous colitis 
and immune system activation in interleukin鄄  10鄄  deficient mice 
[J]. Infect Immun, 1998,66(11):5224-5231. 
Kado S, Uchida K, Funabashi H, et al. Intestinal microflora are 
necessary for development of spontaneous adenocarcinoma of 
the large intestine in T鄄  cell receptor beta chain and p53 
double鄄  knockout mice [J]. Cancer Res, 2001,61(6):2395-2398. 
咱102暂 
咱103暂 
咱104暂 
咱105暂 
咱106暂 
咱107暂 
咱108暂 
咱109暂 
咱110暂 
咱111暂 
咱112暂 
咱113暂 
咱114暂 
咱115暂 
咱116暂 
咱117暂 
咱118暂 
咱119暂 
咱120暂 
咱121暂 
咱122暂 
咱123暂 
咱124暂 
咱125暂 
咱126暂 
咱127暂 
咱128暂 
咱129暂 
咱130暂 
咱131暂 
咱132暂 
咱133暂 
Yunguang Tong et al. Mouse models of colorectal cancer 
460
Chin J Cancer; 2011; Vol. 30 Issue 7 www.cjcsysu.com 
Engle SJ, Ormsby I, Pawlowski S, et al. Elimination of colon 
cancer in germ鄄  free transforming growth factor beta 1鄄  deficient 
mice [J]. Cancer Res, 2002,62(22):6362-6366. 
Greten FR, Eckmann L, Greten TF, et al. Ikkbeta links 
inflammation and tumorigenesis in a mouse model of colitis鄄  
associated cancer [J]. Cell, 2004,118(3):285-296. 
Burstein E, Fearon ER. Colitis and cancer: a tale of 
inflammatory cells and their cytokines [J]. J Clin Invest, 
2008,118(2):464-467. 
Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2鄄  
dependent regulation of innate and adaptive immunity in the 
intestinal tract [J]. Science, 2005,307(5710):731-734. 
Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in crohn's 
disease potentiates NF鄄  kappaB activity and IL鄄  1beta 
processing [J]. Science, 2005,307(5710):734-738. 
Fukata M, Chen A, Vamadevan AS, et al. Toll鄄  like receptor鄄  4
promotes the development of colitis鄄  associated colorectal 
tumors [J]. Gastroenterology, 2007,133(6):1869-1881. 
Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF鄄  alpha 
in mice reduces colorectal carcinogenesis associated with 
chronic colitis [J]. J Clin Invest, 2008,118(2):560-570. 
Velcich A, Yang W, Heyer J, et al. Colorectal cancer in mice 
genetically deficient in the mucin muc2 [J]. Science, 2002,295 
(5560):1726-1729. 
Velcich A, Palumbo L, Selleri L, et al. Organization and 
regulatory aspects of the human intestinal mucin gene (muc2) 
locus [J]. J Biol Chem, 1997,272(12):7968-7976. 
van Klinken BJ, Einerhand AW, Duits LA, et al. Gastrointestinal 
expression and partial cDNA cloning of murine muc2 [J]. Am J 
Physiol, 1999,276(1 Pt 1):G115-124. 
Fodde R, Edelmann W, Yang K, et al. A targeted chain鄄  
termination mutation in the mouse apc gene results in multiple 
intestinal tumors [J]. Proc Natl Acad Sci U S A, 1994,91(19): 
8969-8973. 
Bi X, Fang W, Wang LS, et al. Black raspberries inhibit 
intestinal tumorigenesis in apc1638 +/- and muc2 -/- mouse 
models of colorectal cancer [J]. Cancer Prev Res (Phila), 
2010,3(11):1443-1450. 
Yang K, Popova NV, Yang WC, et al. Interaction of muc2 and 
apc on wnt signaling and in intestinal tumorigenesis: potential 
role of chronic inflammation [J]. Cancer Res, 2008,68 (18): 
7313-7322. 
Segal NH, Saltz LB. Evolving treatment of advanced colon 
cancer [J]. Annu Rev Med, 2009,60(207-219. 
Fidler IJ. Orthotopic implantation of human colon carcinomas 
into nude mice provides a valuable model for the biology and 
therapy of metastasis [J]. Cancer Metastasis Rev, 1991,10(3): 
229-243. 
Goldrosen MH. Murine colon adenocarcinoma: immunobiology 
of metastases [J]. Cancer, 1980,45(5 Suppl):1223-1228. 
Inoue Y, Kashima Y, Aizawa K, et al. A new rat colon cancer 
cell line metastasizes spontaneously: biologic characteristics 
and chemotherapeutic response [J]. Jpn J Cancer Res, 
1991,82(1):90-97. 
Hoffman RM. Orthotopic metastatic (metamouse) models for 
discovery and development of novel chemotherapy [J]. 
Methods Mol Med, 2005,111:297-322. 
Sun FX, Sasson AR, Jiang P, et al. An ultra鄄  metastatic model 
of human colon cancer in nude mice [J]. Clin Exp Metastasis, 
1999,17(1):41-48. 
Kashtan H, Rabau M, Mullen JB, et al. Intra鄄  rectal injection of 
tumour cells: a novel animal model of rectal cancer [J]. Surg 
Oncol, 1992,1(3):251-256. 
Boni L, Benevento A, Dionigi G, et al. Injection of colorectal 
cancer cells in mesenteric and antimesenteric sides of the 
colon results in different patterns of metastatic diffusion: an 
experimental study in rats [J]. World J Surg Oncol, 2005,3:69. 
Cespedes MV, Espina C, Garcia鄄  Cabezas MA, et al. 
Orthotopic microinjection of human colon cancer cells in nude 
mice induces tumor foci in all clinically relevant metastatic sites 
[J]. Am J Pathol, 2007,170(3):1077-1085. 
Flatmark K, Maelandsmo GM, Martinsen M, et al. Twelve 
colorectal cancer cell lines exhibit highly variable growth and 
metastatic capacities in an orthotopic model in nude mice [J]. 
Eur J Cancer, 2004,40(10):1593-1598. 
Giavazzi R, Jessup JM, Campbell DE, et al. Experimental nude 
mouse model of human colorectal cancer liver metastases [J]. 
J Natl Cancer Inst, 1986,77(6):1303-1308. 
Wagner HE, Toth CA, Steele GD, Jr., et al. Metastatic potential 
of human colon cancer cell lines: relationship to cellular 
differentiation and carcinoembryonic antigen production [J]. 
Clin Exp Metastasis, 1992,10(1):25-31. 
Hamada K, Monnai M, Kawai K, et al. Liver metastasis models 
of colon cancer for evaluation of drug efficacy using NOD/Shi鄄  
scid IR2Rgammanull (NOG) mice [J]. Int J Oncol, 2008,32(1): 
153-159. 
Lafreniere R, Rosenberg SA. A novel approach to the 
generation and identification of experimental hepatic 
metastases in a murine model [J]. J Natl Cancer Inst, 1986,76 
(2):309-322. 
Casillas S, Dietz DW, Brand MI, et al. Perfusion to colorectal 
cancer liver metastases is not uniform and depends on tumor 
location and feeding vessel [J]. J Surg Res, 1997,67(2):179- 
185. 
Dunnington DJ, Buscarino C, Gennaro D, et al. 
Characterization of an animal model of metastatic colon 
carcinoma [J]. Int J Cancer, 1987,39(2):248-254. 
Ku Y, Kusunoki N, Shiotani M, et al. Stimulation of 
haematogenous liver metastases by ischaemia鄄  reperfusion in 
rats [J]. Eur J Surg, 1999,165(8):801-807. 
Doi K, Horiuchi T, Uchinami M, et al. Neutrophil elastase 
inhibitor reduces hepatic metastases induced by ischaemia鄄  
reperfusion in rats [J]. Eur J Surg, 2002,168(8-9):507-510. 
Ravikumar TS, D'Emilia J, Cocchiaro C, et al. Experimental 
liver metastasis. Implications of clonal proclivity and organ 
specificity [J]. Arch Surg, 1989,124(1):49-54. 
Hagenaars M, Ensink NG, Basse PH, et al. The microscopic 
anatomy of experimental rat cc531 colon tumour metastases: 
consequences for immunotherapy? [J]. Clin Exp Metastasis, 
2000,18(2):189-196. 
Thomas C, Nijenhuis AM, Timens W, et al. Liver metastasis 
model of colon cancer in the rat: immunohistochemical 
characterization [J]. Invasion Metastasis, 1993,13(2):102-112. 
Mook OR, Van Marle J, Vreeling鄄  Sindelarova H, et al. 
Visualization of early events in tumor formation of egfp鄄  
transfected rat colon cancer cells in liver [J]. Hepatology, 
2003,38(2):295-304. 
Rodenbach M, Eyol E, Seelig MH, et al. Combination treatment 
of CC531鄄  Lac鄄  Z rat liver metastases by chemoembolization 
with pemetrexed disodium and gemcitabine [J]. J Cancer Res 
Clin Oncol, 2005,131(5):289-299. 
Liu DL, Radnell M, Svanberg K, et al. Immunotherapy in liver 
tumors: III. A new experimental model of metastatic liver 
tumors from colorectal carcinoma for cytokine therapy [J]. 
Cancer Lett, 1995,88(2):211-219. 
Alves A, Charre L, Panis Y, et al. Total vascular exclusion of 
咱134暂 
咱135暂 
咱136暂 
咱137暂 
咱138暂 
咱139暂 
咱140暂 
咱141暂 
咱142暂 
咱143暂 
咱144暂 
咱145暂 
咱146暂 
咱147暂 
咱148暂 
咱149暂 
咱150暂 
咱151暂 
咱152暂 
咱153暂 
咱154暂 
咱155暂 
咱156暂 
咱157暂 
咱158暂 
咱159暂 
咱160暂 
咱161暂 
咱162暂 
咱163暂 
咱164暂 
咱165暂 
咱166暂 
咱167暂 
咱168暂 
咱169暂 
咱170暂 
咱171暂 
Yunguang Tong et al. Mouse models of colorectal cancer 
461
Chinese Journal of Cancer Chin J Cancer; 2011; Vol. 30 Issue 7 
Submit your next manuscript to 
and take full advantage of: 
窑Open access 
窑No charge to authors 
窑Quickly published 
窑Thorough peer review 
窑Professionally edited 
窑No space constraints 
窑 Indexed by PubMed, CA, and Google Scholar 
Submit your manuscript at 
www.cjcsysu.com 
the liver enhances the efficacy of retroviral鄄  mediated associated 
thymidine kinase and interleukin鄄  2 genes transfer against 
multiple hepatic tumors in rats [J]. Surgery, 2003,133(6):669- 
677. 
Shinozaki K, Ebert O, Woo SL. Treatment of multi鄄  focal 
colorectal carcinoma metastatic to the liver of immune鄄  
competent and syngeneic rats by hepatic artery infusion of 
oncolytic vesicular stomatitis virus [J]. Int J Cancer, 2005,114 
(4):659-664. 
Van Hillegersberg R, Kort WJ, Vermeij M, et al. Treatment of 
experimental liver metastases with a noncontact neodymium: 
Yag laser [J]. J Surg Res, 1992,53(2):128-135. 
van Duijnhoven FH, Tollenaar RA, Terpstra OT, et al. 
Locoregional therapies of liver metastases in a rat cc531 
coloncarcinoma model results in increased resistance to tumour 
rechallenge [J]. Clin Exp Metastasis, 2005,22(3):247-253. 
Rothbarth J, Woutersen RA, Sparidans RW, et al. Melphalan 
antitumor efficacy and hepatotoxicity: the effect of variable 
infusion duration in the hepatic artery [J]. J Pharmacol Exp 
Ther, 2003,305(3):1098-1103. 
Carlsson G, Ekelund L, Hafstrom L, et al. Effects of hepatic 
artery ligation and intraarterial embolization on liver tumor 
growth --an experimental study in rats [J]. J Surg Oncol, 
1981,17(3):249-261. 
Mack P, Jeppsson B, Widlus D, et al. Combined intermittent 
dearterialization and intraperitoneal 5鄄  fluorouracil administration 
for liver tumours in the rat [J]. Eur J Cancer Clin Oncol, 
1988,24(5):909-913. 
Sturesson C, Liu DL, Stenram U, et al. Hepatic inflow occlusion 
increases the efficacy of interstitial laser鄄  induced thermotherapy 
in rat [J]. J Surg Res, 1997,71(1):67-72. 
Lechaux D, Gervais A, Dazord L, et al. Adoptive 
immunotherapy monitored by micro鄄  MRI in experimental 
colorectal liver metastasis [J]. Anticancer Res, 2002,22 (1A): 
151-158. 
Rashidi B, Gamagami R, Sasson A, et al. An orthotopic mouse 
model of remetastasis of human colon cancer liver metastasis 
[J]. Clin Cancer Res, 2000,6(6):2556-2561. 
咱172暂 
咱173暂 
咱174暂 
咱175暂 
咱176暂 
咱177暂 
咱178暂 
咱179暂 
咱180暂 
Yunguang Tong et al. Mouse models of colorectal cancer 
462
